Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06099769 | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | recruiting | Phase 2 | 201 | Memorial Sloan Kettering Cancer CenterOTHER | 1 |
| Feb 25, 2026 |
| clinicaltrials |
| NCT06802757 | Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer(PRISM-TNBC) | recruiting | Phase 2 | 72 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06016387 | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | recruiting | Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07193394 | Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer(H3RAKLES) | recruiting | Phase 2 | 20 | Institut CurieOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04683679 | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05074290 | Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 74 | University of FloridaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06291064 | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 85 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06348134 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | recruiting | Phase 2 | 74 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06517212 | Tirzepatide Weight Loss for MRD+ Early Breast Cancer(TRIM-EBC) | recruiting | Phase 2 | 48 | Baylor Research InstituteOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07071038 | Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients(SWIVEL) | recruiting | Phase 2 | 62 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07208149 | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 42 | Shenzhen Majory Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 220 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07188246 | Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer(BRINK) | recruiting | Phase 2 | 40 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07376538 | Response-Based Local Therapy for Regionally Advanced Breast Cancer | recruiting | Phase 2 | 157 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06064812 | A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. | recruiting | Phase 1 / Phase 2 | 99 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07401537 | Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 416 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07393425 | Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer | recruiting | Phase 2 | 50 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394218 | ctDNA-guided Treatment Decision-making | recruiting | Phase 2 | 122 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07383818 | Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) | recruiting | Phase 2 | 111 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT04680715 | Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer(RPOS+2) | recruiting | Phase 2 | 40 | Centre Antoine LacassagneOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03804944 | Converting HR+ Breast Cancer Into an Individualized Vaccine(CBCV) | recruiting | Phase 2 | 100 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06715826 | Target-specific immunoPET Imaging of Breast Cancer | recruiting | Phase 1 / Phase 2 | 200 | RenJi HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07371208 | Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer(ST-A-TN) | recruiting | Phase 2 | 40 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05693766 | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort(INSIGHT) | recruiting | Phase 2 | 64 | Sonya ReidOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05933395 | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor(GERTRUDE) | recruiting | Phase 2 | 135 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05860465 | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 2 / Phase 3 | 254 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06682195 | Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) | recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06167694 | Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 146 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06559540 | Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer(SWIFT RT) | recruiting | Phase 2 | 220 | Washington University School of MedicineOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06967103 | QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer | recruiting | Phase 2 | 238 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327021 | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC(NOGA) | recruiting | Phase 2 | 54 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07002177 | A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC | recruiting | Phase 1 / Phase 2 | 196 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06690840 | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients(AZALEA) | recruiting | Phase 2 | 45 | European Institute of OncologyOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05728268 | Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index | recruiting | Phase 2 | 64 | Shantou Central HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07314073 | [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer | recruiting | Phase 2 | 85 | Asan Medical CenterOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07037199 | Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer | recruiting | Phase 2 | 45 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06452394 | NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline | recruiting | Phase 2 | 50 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06596018 | Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy | recruiting | Phase 1 / Phase 2 | 96 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04965766 | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer(ICARUS BREAST) | recruiting | Phase 2 | 139 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06085742 | BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer(BRE-08) | recruiting | Phase 2 | 25 | University of Illinois at ChicagoOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06498154 | Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy | recruiting | Phase 2 | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2026source: clinicaltrials